Relay Therapeutics (RLAY) Receivables - Net (2020 - 2023)

Relay Therapeutics (RLAY) has reported Receivables - Net for 4 consecutive years, with $211000.0 the latest figure, recorded in Q3 2023.

• In Q3 2023, Receivables - Net fell 95.69% year-over-year to $211000.0; the TTM figure through Sep 2023 stood at $211000.0 (down 95.69% YoY), while the FY2022 annual figure was $306000.0, down 93.26% from the prior year.
• Receivables - Net improved to $211000.0 in Q3 2023 per RLAY's latest filing, from $78000.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $75.0 million in Q4 2020 and bottomed at $78000.0 in Q2 2023.
• Historically, Receivables - Net has averaged $9.3 million across 4 years, with a median of $4.4 million in 2021.
• Annual changes were most pronounced in 2022 — Receivables - Net advanced 15.27% — and 2023, when it plunged 95.69%.
• Relay Therapeutics' Receivables - Net stood at $75.0 million in 2020, then tumbled by 93.95% to $4.5 million in 2021, then sank by 93.26% to $306000.0 in 2022, then sank by 31.05% to $211000.0 in 2023.
• Business Quant data shows RLAY's Receivables - Net at $211000.0 in Q3 2023, $78000.0 in Q2 2023, and $4.9 million in Q1 2023.